论文部分内容阅读
目的评价重组人干扰素α2b喷雾剂治疗手足口病的临床疗效。方法收治手足口病患儿174例,随机分为治疗组88例和对照组86例。两组均给予热毒宁注射液、利巴韦林静滴治疗。治疗组在对照组的基础上增加重组人干扰素α2b喷雾剂局部治疗。比较两组在发热消退时间、口腔疱疹消退时间、手足臀部疱疹消退时间及总病程等方面的变化和差异。结果治疗组发热消退时间、口腔疱疹消退时间、手足臀部疱疹消退时间及总病程等均较对照组明显缩短,差异有统计学意义(P<0.05)。结论重组人干扰素α2b喷雾剂治疗手足口病疗效显著,临床无明显不良反应。
Objective To evaluate the clinical efficacy of recombinant human interferon α2b spray in the treatment of hand, foot and mouth disease. Methods 174 cases of HFMD were randomly divided into treatment group (88 cases) and control group (86 cases). Both groups were given heat poisoning injection, ribavirin intravenous infusion. Treatment group in the control group based on the addition of recombinant human interferon α2b spray local treatment. The changes and differences between the two groups in fever subsidence time, oral herpes subsidence time, hand and foot hip herpes subsidence time and the total duration of disease were compared. Results The treatment group fever subsided time, oral herpes subsided time, hand and foot herpes herpes subsided time and the total duration of disease were significantly shorter than the control group, the difference was statistically significant (P <0.05). Conclusion Recombinant human interferon α2b spray treatment of hand, foot and mouth disease has significant effect, no clinically significant adverse reactions.